Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 575 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genotype Clear all
Completed No phase listed Observational Accepts healthy volunteers

Biological Specimen Collection for Laboratory Methods Development and Training Purposes

NCT00025831
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 1:48 AM EDT
Completed No phase listed Observational Results available

Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact

NCT01688895
View directory record Official record
Conditions
Erythropoietic Protoporphyria, EPP, X-Linked Protoporphyria, XLP, XLPP, X-Linked Dominant Erythropoietic Protoporphyria, XLEPP, XLDP
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 21, 2026, 1:48 AM EDT
Terminated No phase listed Observational

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

NCT01465516
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Selumetinib in Cancers With BRAF Mutations

NCT00888134
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Selumetinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • Charlestown, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Not applicable Interventional

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

NCT00334464
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Standard of care or genotyping dosing of warfarin dosing
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

NCT01851330
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 4 Interventional

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

NCT00926614
View directory record Official record
Conditions
Hepatitis c
Interventions
pioglitazone (Actos), atorvastatin (Lipitor)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Not applicable Interventional

A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression

NCT02189057
View directory record Official record
Conditions
Depression, Mood Disorder, Bipolar
Interventions
AssureRx GeneSight genotyping results, Treatment as usual
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

NCT01058512
View directory record Official record
Conditions
Hepatitis C
Interventions
NOV-205
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

NCT02906202
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
LentiGlobin BB305 Drug Product
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 21, 2026, 1:48 AM EDT
Active, not recruiting Not applicable Interventional

CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

NCT06565546
View directory record Official record
Conditions
Ventral Hernia
Interventions
Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin, Acetaminophen and Gabapentin: standard postoperative pain medications
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 1:48 AM EDT
Terminated Phase 2 Interventional

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

NCT01384383
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
GS-5885, GS-9451, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

GS-7977 With Ribavirin for Hepatitis C (SPARE)

NCT01441180
View directory record Official record
Conditions
Hepatitis C
Interventions
GS7977, RBV
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 21, 2026, 1:48 AM EDT
Completed No phase listed Observational

Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly

NCT00609635
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD

NCT02834650
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Cardiac MRI with contrast, Cardiac MRI without contrast, Blood Test, Heart Rate, Pulmonary Function Test, Genetic Testing, Repeat MRI scan
Other
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years · Male only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Orange, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

NCT01221298
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Early Phase 1 Interventional Results available

RHD Genotype Matched Red Cells for Anti-D

NCT04156906
View directory record Official record
Conditions
Sickle Cell Disease, Anti-D Antibodies
Interventions
D+ RH genotype matched red cell units for transfusion
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 21, 2026, 1:48 AM EDT
Completed No phase listed Observational

Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping

NCT02161068
View directory record Official record
Conditions
ADPKD
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

NCT00869661
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC

NCT00926120
View directory record Official record
Conditions
Hepatitis C
Interventions
Mogroside sweetener (PureLo)
Dietary Supplement
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 21, 2026, 1:48 AM EDT
Completed No phase listed Observational

Primary Hyperoxaluria Mutation Genotyping/Phenotyping

NCT02340689
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Genetic Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Day and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 21, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 21, 2026, 1:48 AM EDT